CompletedPhase 1NCT05123222
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Anna Durbin, MDJohns Hopkins University
- Intervention
- ZIKV-SJRP/2016-184 Strain(biological)
- Enrollment
- 56 target
- Eligibility
- 18-40 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05123222 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT04398901Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenChildren's National Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation
- RECRUITINGNCT01386424Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsNational Institute of Allergy and Infectious Diseases (NIAID)